It is not possible to generalize how much life expectancy is typically associated with interstitial fibrosis of the lungs due to dermatomyositis. It is not possible to directly determine how much life expectancy is due to the varying degrees of disease progression. When dermatomyositis interstitial lung disease is properly treated in a timely and compliant manner, the disease is better controlled, the patient’s prognosis is better, and the impact on life expectancy is reduced. Dermatomyositis may be an immune-mediated disease induced by infectious and noninfectious factors in genetically susceptible individuals. It usually presents with proximal muscle weakness of the extremities, periorbital rash, and mechanic’s hand, and pulmonary involvement is a common extramuscular manifestation. Interstitial pneumonia is the most common lung lesion, and some patients may present with rapidly progressive interstitial pneumonia that is life-threatening. Treatment needs to follow the principle of individualization, under the guidance of doctors with glucocorticoid drugs, such as hydrocortisone or prednisone, etc., can also be combined with immunosuppressants such as methotrexate, cyclophosphamide, cyclosporine, etc.. Attention to treatment and care measures in life can control the development of the disease and avoid serious life-threatening. Dermatomyositis leading to interstitial fibrosis of the lungs physical condition and disease development will affect the patient’s life expectancy, it is recommended to go to the hospital in a timely manner to avoid delays.